Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novavax and Allergan terminate agreement for Estrasorb
Under the termination agreement, Novavax will complete the manufacture of remaining orders for the product and plans to close its Philadelphia manufacturing facility over the next few months.
Under the termination agreement, Novavax will complete the manufacture of remaining orders for the product and plans to close its Philadelphia manufacturing facility over the next few months.
Kosan said that it does not expect the termination of its collaborative research, development and commercialization agreement with Roche to impact its financial guidance for 2007 due to
This novel drug (Lu AA24530) discovered by Lundbeck, belongs to a new chemical class and represents an approach that is markedly different to any currently marketed antidepressants,according to
The company reported Q3 2007 net earnings of $858 million, or $0.43 per diluted share, compared to $338 million, or $0.17 per diluted share for the same period
The primary objectives of the trial include determining the minimum effective immunomodulatory dose of cyclophosphamide to obtain successful immune modulation. Secondary objectives include the safety profile of the
The data showed that 68% of the 34 patients evaluated for tumor response had clinical benefit. Ten patients had partial responses (eight confirmed, two not yet confirmed), and
The Horizons AMI trial compared Angiomax to heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in more than 3,600 patients presenting with a heart attack. Horizons AMI demonstrated
The second-generation product, BSI-401, is BiPar’s new class of cancer therapies known as poly-ADP-ribose polymerase inhibitors. In animals with orthotopic human pancreatic tumors, BSI-401 significantly reduced tumor burden
The trial will evaluate the safety and pharmacology of vitamin D5 analog, MN-201 in patients with advanced tumors in various cancers. The protocol for the clinical trial is
HCV RNA polymerase inhibitor (R7128) is a prodrug of PSI-6130, an oral cytidine nucleoside analog, which is being developed through Pharmasset’s collaboration with Roche. Pharmasset is currently enrolling